Oct. 2, 2025
| Today’s news and insights for biopharma leaders
In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population.
|
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.
|
The company is working on T cell engagers and other multifunctional antibodies, led by a prospect it believes might be helpful treating the vast majority of colorectal cancer cases.
|
Proactive selection can help avoid costly fixes: The impact of label stock quality on CDMOs and pharmaceutical companies.
|
The company has received a “limited number” of non-binding proposals, mostly from groups of financial investors, for a business that was once its primary focus.
|
The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while prioritizing investments elsewhere.
|
|
Since 2022, Chinese companies account for 31% of the total global drug market. Learn how Western pharma companies can collaborate with China’s booming bioscience sector in this playbook.
|
|
From Our Library
Trendline
Supported by 10x Genomics
|
Survey Report
Custom content for Qiagen
|
Trendline
Supported by Catalent
|
Playbook
Custom content for Lonza
|
| 
